000			03169cam a2200349 a 4500
003			EG-GiCUC
005			20250223031353.0
008			151213s2014 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.23.M.Sc.2014.Ah.O
100	0		_aAhmed Elsayed Morsy
245	1	0	_aOvarian cancer pattern : _bAt nemrock during the period 2005-2011 / _cAhmad Elsayed Morsy ; Supervised Emad Hamada , Emad Ezzat , Raafat Ragaie
246	1	5	_aدراسة الكلينيوباثولوجيا ونتائح علاج اورام المبيض الخبيثة : _bدراسة استرجاعية من سنة2005-2011
260			_aCairo : _bAhmed Elsayed Morsy , _c2014
300			_a182 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology-Clinical
520			_aPatients : Female patients between the ages of 18-80 yrs. Baseline Hematological, Renal and Liver laboratory profiles were within accepted ranges. Patients were surgically fit to undergo radical surgery. Patients had to be ECOG Performance status 0-2 to start chemotherapy Patients will pathologically proven Ovarian Cancer and records showed follow-up for at least 6 months. Women who stopped their treatment for non-medical reasons (social or psychological or financial). Were excluded .Any records of other malignancy at other sites were excluded from this analysis. Methodology: Records were evaluated to answer if the patient underwent Radical surgery, received adjuvant systemic treatment, the type of chemotherapy, duration of the adjuvant treatment and the period between last cycle od adjuvant and any disease relapse. For metastatic patients; what type of chemotherapy used as first line and its response, second line and its response and if third was given. Also the study assess the common drug related toxicities and the qualit y of life for the patients. Results: DFS period is calculated as the interval through the first Progression after receiving primary treatment. Progression was detected clinically and/or radiologically, after receiving adjuvant Chemotherapy. OS period is measured as the interval between the date of histo-pathological confirmation of disease (either Radical surgery or biopsies) and death or date of the last follow-up evaluation. Conclusion: We found that in EOC subtype the patients are almost a decade younger than western patients. The results of DFS and OS were comparable to the international statistics. There is no clear guidelines for second line protocols. Limited financial resources did not affect the management of patients concerning radical surgery and adjuvant therapy
530			_aIssued also as CD
653		4	_aEpithelial type
653		4	_aOptimal surgery
653		4	_aOvarian cancer
700	0		_aEmad Ezzat , _eSupervisor
700	0		_aEmad Hamada , _eSupervisor
700	0		_aRaafat Ragaie , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c53921 _d53921